PL3096798T3 - Białka wiążące kalikreinę osocza i ich zastosowanie w leczeniu obrzęku naczynioruchowego - Google Patents

Białka wiążące kalikreinę osocza i ich zastosowanie w leczeniu obrzęku naczynioruchowego

Info

Publication number: PL3096798T3
Authority: PL; Poland
Prior art keywords: binding proteins; plasma kallikrein; hereditary angioedema; kallikrein binding; treating hereditary
Prior art date: 2014-01-21

Application number

PL15740774T

Other languages

English (en)

Inventor

Yung CHYUNG

Daniel J. Sexton

Christopher Tenhoor

Jon A. Kenniston

Ryan Faucette

Ryan Iarrobino

Joseph BIEDENKAPP

Burt Adelman

Original Assignee

Takeda Pharmaceutical Company Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-01-21

Filing date

2015-01-21

Publication date

2021-07-26

2015-01-21 Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited

2021-07-26 Publication of PL3096798T3 publication Critical patent/PL3096798T3/pl

Links

206010019860 Hereditary angioedema Diseases 0.000 title 1
102000003827 Plasma Kallikrein Human genes 0.000 title 1
108090000113 Plasma Kallikrein Proteins 0.000 title 1
102000023732 binding proteins Human genes 0.000 title 1
108091008324 binding proteins Proteins 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/03—Phosphotransferases with a nitrogenous group as acceptor (2.7.3)
- C12Y207/03002—Creatine kinase (2.7.3.2)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21034—Plasma kallikrein (3.4.21.34)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Diabetes (AREA)
Hematology (AREA)
Zoology (AREA)
General Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Microbiology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Enzymes And Modification Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

PL15740774T 2014-01-21 2015-01-21 Białka wiążące kalikreinę osocza i ich zastosowanie w leczeniu obrzęku naczynioruchowego PL3096798T3 (pl)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US201461929716P	2014-01-21	2014-01-21
US201461944361P	2014-02-25	2014-02-25
US201462021397P	2014-07-07	2014-07-07
EP15740774.3A EP3096798B1 (en)	2014-01-21	2015-01-21	Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
PCT/US2015/012212 WO2015112578A1 (en)	2014-01-21	2015-01-21	Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema

Publications (1)

Publication Number	Publication Date
PL3096798T3 true PL3096798T3 (pl)	2021-07-26

Family

ID=53681890

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL15740774T PL3096798T3 (pl)	2014-01-21	2015-01-21	Białka wiążące kalikreinę osocza i ich zastosowanie w leczeniu obrzęku naczynioruchowego

Country Status (18)

Country	Link
US (2)	US11084884B2 (pl)
EP (2)	EP3096798B1 (pl)
JP (3)	JP6845012B2 (pl)
KR (4)	KR102424183B1 (pl)
CN (2)	CN116585468A (pl)
AU (3)	AU2015209481C1 (pl)
BR (1)	BR112016016916B1 (pl)
CA (1)	CA2937329C (pl)
DK (1)	DK3096798T3 (pl)
EA (1)	EA038532B1 (pl)
ES (1)	ES2856076T3 (pl)
IL (3)	IL246864B (pl)
MX (2)	MX2016009428A (pl)
NZ (2)	NZ761006A (pl)
PL (1)	PL3096798T3 (pl)
PT (1)	PT3096798T (pl)
WO (1)	WO2015112578A1 (pl)
ZA (2)	ZA201605342B (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3459564B1 (en)	2010-01-06	2021-10-27	Takeda Pharmaceutical Company Limited	Plasma kallikrein binding proteins
KR102169651B1 (ko)	2011-01-06	2020-10-23	다이액스 코포레이션	혈장 칼리크레인 결합 단백질
US11156612B2 (en)	2013-01-20	2021-10-26	Takeda Pharmaceutical Company Limited	Methods of determining levels of cleaved and/or intact kininogen
CN111704672B (zh)	2013-03-15	2024-06-04	武田药品工业株式会社	抗血浆激肽释放酶抗体
JP6657098B2 (ja)	2013-10-21	2020-03-04	ダイアックスコーポレーション	自己免疫疾患の診断と治療
ES2837858T3 (es)	2013-10-21	2021-07-01	Dyax Corp	Ensayos para determinar biomarcadores del sistema calicreína plasmática
ES2856076T3 (es)	2014-01-21	2021-09-27	Takeda Pharmaceuticals Co	Proteínas de unión a calicreína plasmática y usos de las mismas en el tratamiento de angioedema hereditario
IL247942B (en)	2014-03-27	2022-09-01	Dyax Corp	Compositions and methods for drops in macular edema as a result of diabetes
EP3916020A1 (en) *	2015-03-30	2021-12-01	Dyax Corp.	Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack
WO2017035263A1 (en) *	2015-08-24	2017-03-02	Biocryst Pharmaceuticals, Inc.	Compositions comprising a plasma kallikrein inhibitor
PT3365685T (pt) *	2015-10-19	2021-03-01	Dyax Corp	Imunoensaio para detetar cininogénio de elevada massa molecular clivado
IL311156A (en)	2015-12-11	2024-04-01	Takeda Pharmaceuticals Co	Plasma kallikrein inhibitors and their uses in the treatment of hereditary angioedema attack
CN109716129B (zh)	2016-09-16	2023-10-03	武田药品工业株式会社	用于遗传性血管性水肿的rna生物标记
MX2019002932A (es) *	2016-09-16	2019-07-15	Dyax Corp	Biomarcadores proteicos para enfermedades asociadas con el sistema de activacion por contacto.
KR20200067195A (ko) *	2017-10-18	2020-06-11	리젠엑스바이오 인크.	완전-인간 번역후 변형된 항체 치료제
AU2018374219C1 (en)	2017-12-01	2023-05-11	Suzhou Ribo Life Science Co., Ltd.	Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method therefor and use thereof
CN110997917B (zh)	2017-12-01	2024-04-09	苏州瑞博生物技术股份有限公司	一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
CN116375774A (zh)	2017-12-29	2023-07-04	苏州瑞博生物技术股份有限公司	缀合物及其制备方法和用途
WO2020038377A1 (zh)	2018-08-21	2020-02-27	苏州瑞博生物技术有限公司	一种核酸、含有该核酸的药物组合物和缀合物及其用途
CN111655297A (zh)	2018-09-30	2020-09-11	苏州瑞博生物技术有限公司	一种siRNA缀合物及其制备方法和用途
JP2022534069A (ja) *	2019-05-24	2022-07-27	スーチョウリボライフサイエンスカンパニー、リミテッド	核酸、薬物組成物及び複合体並びに調製方法と使用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5179017A (en)	1980-02-25	1993-01-12	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en)	1980-02-25	1987-01-06	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en)	1980-02-25	1983-08-16	The Trustees Of Columbia University	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4522811A (en)	1982-07-08	1985-06-11	Syntex (U.S.A.) Inc.	Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5374548A (en)	1986-05-02	1994-12-20	Genentech, Inc.	Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es)	1985-06-26	1992-08-01	Liposome Co Inc	Metodo para acoplamiento de liposomas.
US5444156A (en)	1985-07-12	1995-08-22	Temple University-Of The Commonwealth System Of Higher Education	Monoclonal antibodies to human plasma prekallikrein
GB8601597D0 (en)	1986-01-23	1986-02-26	Wilson R H	Nucleotide sequences
WO1987005396A1 (en)	1986-03-03	1987-09-11	Brigham And Women's Hospital	A method for evaluating nephrotoxicity
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US5260203A (en)	1986-09-02	1993-11-09	Enzon, Inc.	Single polypeptide chain binding molecules
US4881175A (en)	1986-09-02	1989-11-14	Genex Corporation	Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4704692A (en)	1986-09-02	1987-11-03	Ladner Robert C	Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5045452A (en)	1988-09-02	1991-09-03	Brigham And Women's Hospital	Method for evaluating nephrotoxicity
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5427908A (en)	1990-05-01	1995-06-27	Affymax Technologies N.V.	Recombinant library screening methods
JP4124480B2 (ja)	1991-06-14	2008-07-23	ジェネンテック・インコーポレーテッド	免疫グロブリン変異体
ES2136092T3 (es)	1991-09-23	1999-11-16	Medical Res Council	Procedimientos para la produccion de anticuerpos humanizados.
US5733743A (en)	1992-03-24	1998-03-31	Cambridge Antibody Technology Limited	Methods for producing members of specific binding pairs
US5827690A (en)	1993-12-20	1998-10-27	Genzyme Transgenics Corporatiion	Transgenic production of antibodies in milk
ATE275583T1 (de)	1994-01-11	2004-09-15	Dyax Corp	KALLIKREINHEMMENDE ßKUNITZ-DOMÄNEß-PROTEINE UND DERIVATEN DAVON
US6265150B1 (en)	1995-06-07	2001-07-24	Becton Dickinson & Company	Phage antibodies
DE19632772A1 (de)	1996-08-14	1998-02-19	Basf Ag	Neue Benzamidine
NZ532896A (en)	2001-11-08	2007-08-31	Pdl Biopharma Inc	Stable liquid pharmaceutical formulation of IGG antibodies including daclizumab and fontolizumab
EP2298278B1 (en)	2002-06-07	2015-11-11	Dyax Corp.	Prevention and reduction of blood loss and inflammatory response
US20070253949A1 (en)	2004-02-03	2007-11-01	Stefan Golz	Diagnostics and Therapeutics for Diseases Associated with Plasma Kallikrein (KLKB1)
US7235530B2 (en)	2004-09-27	2007-06-26	Dyax Corporation	Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
HUE039108T2 (hu)	2006-03-16	2018-12-28	Dyax Corp	Készítmények és eljárások szembetegségek kezelésére
CN101495468A (zh) *	2006-07-31	2009-07-29	艾克提弗赛特制药股份有限公司	血浆激肽释放酶抑制剂
KR100846354B1 (ko)	2007-03-21	2008-07-15	(주) 프로탄바이오	혈청 당단백질부터 분리한 폐암 진단용 마커
CA2693921A1 (en) *	2007-07-20	2009-01-29	Genesys Venture Inc.	Tissue kallikrein for the treatment of diseases associated with amyloid protein
US20090105142A1 (en)	2007-08-23	2009-04-23	Genzyme Corporation	Treatment with kallikrein inhibitors
WO2010080833A1 (en) *	2009-01-06	2010-07-15	Dyax Corp.	Treatment of mucositis with kallikrein inhibitors
CN101928346B (zh)	2009-07-31	2013-01-16	华中科技大学同济医学院附属同济医院	一种抗人组织激肽释放酶单克隆抗体及其制备
EP3459564B1 (en)	2010-01-06	2021-10-27	Takeda Pharmaceutical Company Limited	Plasma kallikrein binding proteins
KR102169651B1 (ko)	2011-01-06	2020-10-23	다이액스 코포레이션	혈장 칼리크레인 결합 단백질
US8691861B2 (en)	2011-04-13	2014-04-08	Activesite Pharmaceuticals, Inc.	Prodrugs of inhibitors of plasma kallikrein
US11156612B2 (en)	2013-01-20	2021-10-26	Takeda Pharmaceutical Company Limited	Methods of determining levels of cleaved and/or intact kininogen
RS58635B1 (sr)	2013-01-20	2019-05-31	Dyax Corp	Procena, testovi i lečenje pkal-posredovanih poremećaja
CN111704672B (zh)	2013-03-15	2024-06-04	武田药品工业株式会社	抗血浆激肽释放酶抗体
ES2856076T3 (es) *	2014-01-21	2021-09-27	Takeda Pharmaceuticals Co	Proteínas de unión a calicreína plasmática y usos de las mismas en el tratamiento de angioedema hereditario
IL247942B (en)	2014-03-27	2022-09-01	Dyax Corp	Compositions and methods for drops in macular edema as a result of diabetes
EP3916020A1 (en)	2015-03-30	2021-12-01	Dyax Corp.	Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack
IL311156A (en)	2015-12-11	2024-04-01	Takeda Pharmaceuticals Co	Plasma kallikrein inhibitors and their uses in the treatment of hereditary angioedema attack
CN109716137B (zh) *	2016-09-16	2023-07-21	武田药品工业株式会社	用于与接触活化***相关的疾病的代谢产物生物标记

2015
- 2015-01-21 ES ES15740774T patent/ES2856076T3/es active Active
- 2015-01-21 NZ NZ761006A patent/NZ761006A/en unknown
- 2015-01-21 JP JP2016547570A patent/JP6845012B2/ja active Active
- 2015-01-21 KR KR1020167022785A patent/KR102424183B1/ko active IP Right Grant
- 2015-01-21 PT PT157407743T patent/PT3096798T/pt unknown
- 2015-01-21 KR KR1020247006911A patent/KR20240033156A/ko active Application Filing
- 2015-01-21 MX MX2016009428A patent/MX2016009428A/es unknown
- 2015-01-21 EP EP15740774.3A patent/EP3096798B1/en active Active
- 2015-01-21 AU AU2015209481A patent/AU2015209481C1/en active Active
- 2015-01-21 US US15/113,297 patent/US11084884B2/en active Active
- 2015-01-21 EP EP20209536.0A patent/EP3848057A1/en active Pending
- 2015-01-21 CA CA2937329A patent/CA2937329C/en active Active
- 2015-01-21 CN CN202310760869.5A patent/CN116585468A/zh active Pending
- 2015-01-21 BR BR112016016916-6A patent/BR112016016916B1/pt active IP Right Grant
- 2015-01-21 PL PL15740774T patent/PL3096798T3/pl unknown
- 2015-01-21 KR KR1020247010766A patent/KR20240049627A/ko active Search and Examination
- 2015-01-21 WO PCT/US2015/012212 patent/WO2015112578A1/en active Application Filing
- 2015-01-21 KR KR1020227025028A patent/KR20220107077A/ko not_active IP Right Cessation
- 2015-01-21 DK DK15740774.3T patent/DK3096798T3/da active
- 2015-01-21 CN CN201580010172.XA patent/CN106132442B/zh active Active
- 2015-01-21 NZ NZ723369A patent/NZ723369A/en unknown
- 2015-01-21 EA EA201691470A patent/EA038532B1/ru unknown
2016
- 2016-07-20 MX MX2021013665A patent/MX2021013665A/es unknown
- 2016-07-20 IL IL246864A patent/IL246864B/en active IP Right Grant
- 2016-08-02 ZA ZA201605342A patent/ZA201605342B/en unknown
2018
- 2018-12-12 IL IL263669A patent/IL263669B/en active IP Right Grant
2019
- 2019-09-12 JP JP2019166361A patent/JP7164502B2/ja active Active
2020
- 2020-07-28 ZA ZA2020/04653A patent/ZA202004653B/en unknown
- 2020-09-02 US US17/010,354 patent/US20210087293A1/en active Pending
- 2020-09-28 AU AU2020244370A patent/AU2020244370B2/en active Active
- 2020-10-14 IL IL278062A patent/IL278062B/en unknown
2022
- 2022-10-20 JP JP2022168140A patent/JP2023015087A/ja active Pending
2024
- 2024-05-23 AU AU2024203436A patent/AU2024203436A1/en active Pending

Also Published As

Publication number	Publication date
KR102424183B1 (ko)	2022-07-26
MX2016009428A (es)	2017-04-13
KR20160122169A (ko)	2016-10-21
JP2020002171A (ja)	2020-01-09
CN106132442A (zh)	2016-11-16
JP6845012B2 (ja)	2021-03-17
US20210087293A1 (en)	2021-03-25
AU2015209481C1 (en)	2020-10-29
DK3096798T3 (da)	2021-03-01
EP3848057A1 (en)	2021-07-14
US20170002094A1 (en)	2017-01-05
CN106132442B (zh)	2023-07-14
ZA201605342B (en)	2020-11-25
BR112016016916B1 (pt)	2023-12-19
NZ761006A (en)	2023-04-28
JP2017503820A (ja)	2017-02-02
ZA202004653B (en)	2022-01-26
AU2024203436A1 (en)	2024-06-13
JP7164502B2 (ja)	2022-11-01
CA2937329A1 (en)	2015-07-30
IL278062A (en)	2020-11-30
US11084884B2 (en)	2021-08-10
AU2015209481A1 (en)	2016-08-25
AU2020244370A1 (en)	2020-10-29
BR112016016916A8 (pt)	2018-05-02
AU2020244370B2 (en)	2024-03-07
IL263669B (en)	2020-10-29
EP3096798A1 (en)	2016-11-30
BR112016016916A2 (pt)	2018-01-23
NZ723369A (en)	2022-12-23
KR20240033156A (ko)	2024-03-12
IL278062B (en)	2022-06-01
EP3096798B1 (en)	2020-11-25
PT3096798T (pt)	2021-02-25
MX2021013665A (es)	2021-12-10
CA2937329C (en)	2022-05-31
EP3096798A4 (en)	2017-08-23
EA201691470A1 (ru)	2016-12-30
KR20220107077A (ko)	2022-08-01
KR20240049627A (ko)	2024-04-16
CN116585468A (zh)	2023-08-15
IL246864B (en)	2018-12-31
IL263669A (en)	2019-01-31
ES2856076T3 (es)	2021-09-27
JP2023015087A (ja)	2023-01-31
WO2015112578A1 (en)	2015-07-30
EA038532B1 (ru)	2021-09-10
AU2015209481B2 (en)	2020-07-30

Publication	Publication Date	Title
IL278062B (en)	2022-06-01	Plasma kallikrein-binding proteins and their uses in the treatment of hereditary angioedema
HK1252937A1 (zh)	2019-06-06	用於治療抑鬱症的方法和試劑盒
IL259570A (en)	2018-07-31	Combined therapy and their uses and methods
ZA201802854B (en)	2019-01-30	Authentication methods and sysyems
IL261140A (en)	2018-10-31	Antibodies against tnf-alpha and functional fragments thereof
EP3209298A4 (en)	2018-06-20	Compositions and methods for treating insomnia
IL259691A (en)	2018-07-31	Plasma kallikrein inhibitors and their uses for the treatment of hereditary angioedema attack
ZA202108600B (en)	2022-03-30	Anti-tnfalpha-antibodies and functional fragments thereof
IL259096A (en)	2018-06-28	Peptides and methods of treating endometriosis using the same
IL261261A (en)	2018-10-31	Antibodies against tnf-alpha and functional fragments thereof
ZA201708223B (en)	2018-11-28	Endostatin fragments and variants for use in treating fibrosis
IL261098A (en)	2018-10-31	Antibodies against tnf-alpha and functional fragments thereof
EP3220908A4 (en)	2018-06-27	Compositions and methods for treating endometriosis
IL261793A (en)	2018-10-31	Anti-tnfalpha antibodies and their functional parts
EP3380468B8 (en)	2020-11-04	Bis-pyridazine compounds and their use in treating cancer
EP3110453A4 (en)	2017-09-27	Tmem100 peptides and variants thereof and their use in treating or preventing diseases or conditions
IL257407A (en)	2019-09-26	Compositions and methods for treating wounds
HUE046688T2 (hu)	2020-03-30	Biztonsági hordozókban végrehajtott javítások
EP3270919A4 (en)	2018-10-24	Compositions and methods for treating hepatocellular carcinoma
GB201418526D0 (en)	2014-12-03	Kit and method for preventing or treating menopausal symptoms